Quarry LP’s Myriad Genetics MYGN Stock Holding History

Quarry LP’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,365	Closed	-$26.8K	–	1976
2025 Q4	$26.8K	Buy	4,365 +2,657	+156%	+$19.3K	﹤0.01%	885
2025 Q3	$12.3K	Buy	+1,708	New	+$10.1K	﹤0.01%	1616
2025 Q1	–	Sell	-180	Closed	-$2.47K	–	1886
2024 Q4	$2.47K	Sell	180 -630	-78%	-$11.6K	﹤0.01%	1455
2024 Q3	$22.2K	Buy	+810	New	+$21.9K	0.01%	1078

Other funds holding MYGN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quarry LP's MYGN Position: Q1 2026 in Review

Quarry LP sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 4,365 shares — an estimated $26.8K sold.

Quarry LP first reported a position in MYGN in Q3 2024 and held it in 4 quarters. The position peaked at $26.8K in Q4 2025. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Quarry LP reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Quarry LP sold 4,365 Myriad Genetics shares in Q1 2026, an estimated $26.8K.
Quarry LP first reported a position in Myriad Genetics in Q3 2024 and held it in 4 quarters.
Quarry LP's Myriad Genetics position peaked at $26.8K in Q4 2025.
203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Quarry LP's 13F filing for Q1 2026, filed 15 May 2026.